Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953371 | 1.00 | SLC2A1 (0.64) | SLC2A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL1546237 | 0.82 | SLC2A1 (0.62) | SLC2A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL27875451 | 0.82 | SLC2A1 (0.62) | SLC2A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL9000418 | 0.79 | SLC2A1 (0.58) | SLC2A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL25042631 | 0.78 | SLC2A1 (1.00) | SLC2A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL30275251 | 0.78 | SLC2A1 (1.00) | SLC2A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL30275111 | 0.78 | SLC2A1 (1.00) | SLC2A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL14988861 | 0.77 | MAPT (0.56) | SLC2A1MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL14988862 | 0.77 | MAPT (0.56) | SLC2A1MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL20337186 | 0.77 | SLC2A1 (0.59) | SLC2A1MAPTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| EP-3956322-B1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-113631535-B | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-3583105-B1 | PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-113710664-B | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-114096532-B | Heterocyclic compounds which inhibit tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2002008201-A2 | BETA-AMINO ACID DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| CN-1327443-A | Substituted anilide compounds | ARVENTIS PHARMACEUTICALS CO LT (GB) | 2001-12-19 | — | — | CN | disclosed |
| EP-1027328-A1 | SUBSTITUTED ANILIDES | Aventis Pharma Limited (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999023063-A1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LIMITED (GB) | 1999-05-14 | — | — | WO | disclosed |
| US-5721259-A | Method of using 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0570294-B1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | UNIV YALE (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5281715-A | 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0570294-A1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | YALE UNIVERSITY (US) | 1993-11-18 | — | — | EP | disclosed |
| US-5207952-A | Polyesters with pendant side chains | UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 1993-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | ATR, CHEK2, CHEK1 | SLC2A1 4689/4885MAPT 1987/4885ADRA2A 3769/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | SLC2A1 4356/4885MAPT 4828/4885ADRA2A 1523/4885 |
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | SLC2A1 2540/4885MAPT 3146/4885ADRA2A 4763/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | SLC2A1 3949/4885MAPT 569/4885ADRA2A 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.